Market Synopsis:

As per Market Research Future (MRFR)’s analysis, the global pharmacogenomics market is set to expand at a CAGR of 5.8% during the forecast period. It is a new development in the field of medical science and aims at developing effective and safe medications. This, in turn, has enabled it to gain much popularity in a short span of time, thus, augmenting the market.

Pharmacogenomics is expected to facilitate the treatment of a wide spectrum of diseases such as cardiovascular diseases, Alzheimer disease, cancer, HIV/AIDS, and asthma among others. An upsurge in the investments for technology advancements is primarily poised to revolutionize the pharmacogenomics market. Furthermore, it also supports the customization of medicine doses according to a person’s genetics. This, in turn, has led to an expansion of the market presence of pharmacogenomics throughout the global healthcare sector.

The biotechnology industry has been burgeoning, and it has paved the way for the growth of the pharmacogenomics market in the recent time. A similar trend is likely to be witnessed in the upcoming years by the market participants. On the flip side, a lack of awareness about the technology and inconsistency in the products are presumed to hold the proliferation of the pharmacogenomics market over the next couple of years.

Competitive Dashboard:

Some of the key players profiled in this report are Myriad Genetics, Inc. (U.S.), GeneTech (U.S.), GeneDx. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), 23andMe, Inc. (U.S.), Future Science Group (U.S.), Assurex Health, Inc. (U.S.), and Pathway Genomics (U.S.).

Market Segmentation:

On the basis of technology, the global pharmacogenomics market has been segmented into microarray, sequencing, polymerase chain reaction, and others. The sequencing segment has been further sub-segmented into Sanger sequencing, pyrosequencing, next-generation sequencing, and others.

On the basis of application, the pharmacogenomics market has been segmented into oncology, cardiology, neurological disorders, and others. The oncology segment has been sub-segmented into breast cancer, lung cancer, and others.

On the basis of end-users, the global pharmacogenomics market has been segmented into hospitals, research organizations, academic institute, and others

Regional Analysis:

The global pharmacogenomics market, by region, has been segmented into Americas, Europe, Asia Pacific, and the Middle East Africa. Americas is expected to dominate the global market owing to the presence of developed economies and an advanced healthcare sector. Furthermore, the increasing patient pool of cardiovascular diseases and rising healthcare expenditure is poised to boost the growth trajectory of the pharmacogenomics market.

Europe is presumed to command the second-largest market share during the forecast period. The primary factors that are expected to complement the growth of the regional pharmacogenomics market include availability of findings, increasing research development activities, and growing support by the government. Also, the consolidation of major country-level markets such as Germany and France are poised to reflect positively on the expansion of the market.

Asia Pacific resonates strong potential for expansion. It has been projected to become the fastest growing regional pharmacogenomics market over the assessment period. Meanwhile, the Middle East Africa is set to exhibit sluggish growth. The laggards restricting the growth of the pharmacogenomics market in the region are low per capita healthcare expenditure and stringent government policies, especially in the African region.

Industry News:

In December 2018, a leading telegenomics technology and services company, Genome Medical, has added pharmacogenomics to its line of genetic services.

In December 2018, ZibdyHealth has become the first health application to make pharmacogenomics simple to use, easy to understand, and useful for everyone by integrating clinical and genomic data.

In December 2018, Genesys Physicians Hospital Organization, a leader in genomics and precision medicine, has selected 2bPrecise pharmacogenomics (PGx) solution for improving medication safety and overall patient care.

In December 2018, OneOme, co-developed by Mayo Clinic, has announced that it has received approval from New York State Department of Health for offering pharmacogenomic testing.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America